BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/31/2024 7:20:09 AM | Browse: 348 | Download: 1108
Publication Name World Journal of Transplantation
Manuscript ID 90949
Country United Kingdom
ISSN 2220-3230 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Transplantation
Manuscript Type Observational Study
Article Title Impact of hepatitis B immunoglobulin mode of administration on treatment experiences of patients after liver transplantation: Results from an online survey
Manuscript Source Unsolicited Manuscript
All Author List Giorgia Rizza, Kyriaki Glynou and Masha Eletskaya
ORCID
Author(s) ORCID Number
Giorgia Rizza http://orcid.org/0000-0002-8358-6769
Kyriaki Glynou http://orcid.org/0000-0001-6662-3639
Masha Eletskaya http://orcid.org/0000-0002-9540-407X
Funding Agency and Grant Number
Corresponding Author Masha Eletskaya, MSc, Director, Director, N/A, Lumanity Insight (Cello Health Insight), Great Suffolk Yard, 2nd Floor, 131 Great Suffolk Street, London SE1 1PP, United Kingdom. masha.eletskaya@lumanity.com
Key Words Hepatitis B immunoglobulin; Liver transplantation; Subcutaneous; Intramuscular; Intravenous; Patient satisfaction
Core Tip Hepatitis B immunoglobulin (HBIG) combined with a potent nucleos(t)ide analog is recommended in patients undergoing liver transplantation for hepatitis B virus-associated disease. A survey was conducted to determine patients’ thoughts about three forms of HBIG treatment administration - subcutaneous (SC), intramuscular, and intravenous. Regarding current treatment, SC HBIG had the least negative impact on emotional well-being and social life, was most convenient, easiest to administer and least painful. Considering hypothetical HBIG products, SC was preferred over intramuscular and intravenous for ease of administration, convenience, and pain. For these patients, the most important considerations were ease of use, frequency, duration, and side effects.
Publish Date 2024-07-31 07:20
Citation

Rizza G, Glynou K, Eletskaya M. Impact of hepatitis B immunoglobulin mode of administration on treatment experiences of patients after liver transplantation: Results from an online survey. World J Transplant 2024; 14(3): 90949

URL https://www.wjgnet.com/2220-3230/full/v14/i3/90949.htm
DOI https://dx.doi.org/10.5500/wjt.v14.i3.90949
Full Article (PDF) WJT-14-90949-with-cover.pdf